MLN8054, a selective inhibitor of Aurora A kinase: final results of a phase I clinical trial

被引：1
|
作者：
Cervantes, A. [1 ]
Macarulla, T. [2 ]
Rosello, S. [1 ]
Rodriguez-Braun, E. [1 ]
Baselga, J. [2 ]
Tabernero, J. [2 ]
Liu, H. [5 ]
Chakravarty, A. [3 ]
Bowman, D. [4 ]
Eton, O. [6 ]
机构：
[1] Hosp Clin Univ Valencia, Valencia, Spain
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Millennium Pharmaceut Inc, Canc Pharmacol, Cambridge, MA USA
[4] Millennium Pharmaceut Inc, Mol & Cellular Oncol, Cambridge, MA USA
[5] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
[6] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72213-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：90 / 90
页数：1
相关论文
共 50 条
  • [31] A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.
    Mosse, Y. P.
    Lipsitz, E. G.
    Maris, J. M.
    Weigel, B.
    Adamson, P. C.
    Ingle, M.
    Ahern, C. H.
    Blaney, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies
    Padmanabhan, Swaminathan
    Shea, Thomas C.
    Vose, Julie M.
    Reeder, Craig B.
    Berdeja, Jesus G.
    McDonagh, Kevin T.
    Goy, Andre
    Kelly, Kevin R.
    Zhou, Xiaofei
    Liu, Hua
    Fingert, Howard
    Fowler, Nathan
    BLOOD, 2010, 116 (21) : 1154 - 1154
  • [33] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Cervantes, Andres
    Elez, Elena
    Roda, Desamparados
    Ecsedy, Jeffrey
    Macarulla, Teresa
    Venkatakrishnan, Karthik
    Rosello, Susana
    Andreu, Jordi
    Jung, JungAh
    Sanchis-Garcia, Juan Manuel
    Piera, Adelaida
    Blasco, Inma
    Manos, Laura
    Perez-Fidalgo, Jose-Alejandro
    Fingert, Howard
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4764 - 4774
  • [34] Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
    Mosse, Yael P.
    Lipsitz, Emily
    Fox, Elizabeth
    Teachey, David T.
    Maris, John M.
    Weigel, Brenda
    Adamson, Peter C.
    Ingle, Mark A.
    Ahern, Charlotte H.
    Blaney, Susan M.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 6058 - 6064
  • [35] Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results
    Farag, Sherif
    Zhang, Shuhong
    Suvanna-sankha, Attaya
    Liang, Jing
    O'Bryant, Robyn
    Lisa, Wood
    Gupta, Sushil
    Bray, Mark
    Sidor, Carolyn Fowler
    Abonour, Rafat
    BLOOD, 2010, 116 (21) : 816 - 816
  • [36] Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An Investigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies
    Kelly, Kevin R.
    Padmanabhan, Swaminathan
    Goy, Andre
    Berdeja, Jesus G.
    Reeder, Craig B.
    McDonagh, Kevin T.
    Zhou, Xiaofei
    Danaee, Hadi
    Xiao, Hugh
    Benaim, Ely
    Shea, Thomas C.
    BLOOD, 2011, 118 (21) : 1061 - 1062
  • [37] MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results
    Alvarez, R. H.
    DeMichele, A.
    Mailliez, A.
    Benaim, E.
    Fingert, H.
    Schusterbauer, C.
    Zhang, B.
    Melichar, B.
    CANCER RESEARCH, 2012, 72
  • [38] MLN8237 (ALISERTIB), A SELECTIVE AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC): PHASE 2 RESULTS
    Havel, Libor
    Dees, Claire
    Lockhart, Craig
    Bennouna, Jaafar
    Serwatowski, Piotr
    Liu, Stephen
    Niu, Huifeng
    Badola, Sunita
    Schusterbauer, Claudia
    Ullmann, Claudio Dansky
    Zhang, Bin
    Benaim, Ely
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S221 - S222
  • [39] Phase I and pharmacological study of AZD1152, a selective inhibitor of aurora kinase B
    Boss, D. S.
    Witteveen, P. O.
    Mergui, M.
    van der Sar, J.
    Stockman, P. K.
    Voest, E. E.
    Beijnen, J. H.
    Schellens, J. H. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 782 - 783
  • [40] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345